HUM
Another haircut, same gloomy haircut
Zacks Research went back to the Humana playbook and shaved its Q1 2027 EPS estimate to $8.98 from $8.99. Tiny move? Sure. But in analyst-land, even a penny can signal that the mood is still sour.
What’s behind the fuss
The report also laid out estimates for the next couple of quarters, with Q2 at $6.34 and Q3 at $0.70, while keeping a Strong Sell rating on the stock. Translation: this isn’t exactly a “great things are coming” memo.
Why you should care
Humana has already been dealing with a chorus of cautious brokers. MarketBeat says the consensus rating sits at Hold, with an average target around $222.09, and several firms have recently chopped their own targets too. When the analyst crowd keeps nudging expectations lower, it can cap the stock’s upside even if the company is still posting operational wins.
The annoying part of being right-ish
Humana recently beat quarterly revenue and EPS expectations and reaffirmed its FY2026 EPS guidance at 9.00. It even tossed in a quarterly dividend of $0.885. But in this market, a decent quarter can still get overshadowed by the bigger question: can the company keep healthcare margins from turning into a slow-motion soap opera?
Big picture: Humana is still generating cash and paying dividends, but the analyst herd is clearly not ready to pop the champagne.